Experimental chemicals were procured from standard company such as Panax ginseng extract was obtained from panacea Phytoextracts, India. Sodium selenate and ascorbic acid were obtained from Alfa Aesar, India. Silymarin and curcumin were obtained from Sanat Chemicals, India and quercetin was purchased from Clearsynth, India. Ferrous sulfate, vitamin B₆, vitamin D₃, vitamin B₁₂, calcium chloride, naringenin, trimetazidine (TMZ), 3-(4,5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT), and ethylenediaminetetraacetic acid (EDTA) were procured from Sigma Chemical Co. (St. Louis, MO). Zinc chloride, magnesium gluconate, β-carotene, and calcitriol were purchased from TCI chemicals, Japan. Reverse Transcription Kit, RNeasy Mini Kit, and Syber Green PCR kits were procured from Qiagen, India. All the other chemicals used in this experiment were analytical grade procured from India.

The test formulation constituents and the specific cell line media was used for the treatment with the Biofield Energy. The test formulation was the combination of eleven ingredients such as panax ginseng extract, β-carotene, zinc chloride, calcium chloride, magnesium gluconate, sodium selenate, ferrous sulfate, ascorbic acid, vitamin B₁₂, vitamin D₃, and vitamin B₆. The test formulation constituents and the cell line media were divided into two parts, one portion was considered as the untreated group, where no Biofield Energy Treatment was provided (UT-TI and UT-Med). Further, the untreated group was treated with a sham healer for comparison purposes, who did not have any knowledge about the Biofield Energy Healing Treatment. Another portion of the test formulation and the medium received the Biofield Energy Treatment (The Trivedi Effect^®) remotely by Janice Patricia Kinney, under standard laboratory conditions for ~3 minutes through healer s unique Biofield Energy Transmission process and were referred as the Biofield Energy Treated formulation (BT-TI) and Biofield Energy Treated medium (BT-Med). The Biofield Energy Healer was located in the USA, however the test formulation constituents were located in the research laboratory of Dabur Research Foundation, New Delhi, India. Biofield Energy Healer in this experiment did not visit the laboratory, nor had any contact with the test sample and the medium. After that, the Biofield Energy Treated and untreated test items were kept in similar sealed conditions and used for the study as per the study plan.

All the experimental cells used in this study were counted for cell viability using hemocytometer in 96-well plates at the specific density as mentioned in the Table 1. The cells were then incubated overnight under standard growth conditions to allow cell recovery and exponential growth. Following overnight incubation, cells were treated with different concentrations of test formulations (BT/UT). After respective treatments, the cells were incubated in a CO₂ incubator at 37°C, 5% CO₂, and 95% humidity. After incubation, the plates were taken out and 20 µL of 5 mg/mL of MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide solution was added to all the wells followed by additional incubation for 3 hours at 37°C. The supernatant was aspirated and 150 µL of DMSO was added to each well to dissolve formazan crystals. The absorbance of each well was read at 540 nm using Synergy HT microplate reader. The percentage cytotoxicity at each tested concentration was calculated using Equation 1:

% Cytotoxicity = ((R-X)/R) *100............ (1)

Where, X = Absorbance of treated cells; R = Absorbance of untreated cells

The concentrations exhibiting percentage cytotoxicity <30% was considered as non-cytotoxic.

Cytoprotective effect of the test formulation in selected cells such as human cardiac fibroblasts-HCF; human hepatoma cells-HepG2; and adenocarcinomic human alveolar basal epithelial cells-A549 were counted and plated in suitable medium followed by overnight incubation. Further, the cells were then treated with the test items/positive control at the non-cytotoxic concentrations for 24 hours. After 24 hours, the oxidative stress using 10 mM t-BHP for 3.5 hours was given to the cells. The cells treated with 10 mM of t-BHP alone served as negative control. After 3.5 hours of incubation with t-BHP the above plates were taken out and cell viability was determined by MTT assay. The percentage protection corresponding to each treatment was calculated using equation 2:

% Protection = [(Absorbance_sample-Absorbance_t-BHP)]*100/ [Absorbance_untreated-Absorbance_{t_BHP}]............... (2)

For the estimation of ALP, two cells such as human bone osteosarcoma cells-MG-63 and human endometrial adenocarcinoma cells-Ishikawa were counted using a hemocytometer and plated in 24-well plates at the density corresponding to 1 X 10⁴ cells/well in phenol-free DMEM supplemented with 10% CD-FBS. After the respective treatments, the cells in the above plate were incubated for 48 hours in CO₂ incubator at 37°C, 5% CO₂, and 95% humidity. After 48 hours of incubation, the plates were taken out and processed for the measurement of ALP enzyme activity. The cells were washed with 1 X PBS and lysed by freeze-thaw method i.e., incubation at -80°C for 20 minutes followed by incubation at 37°C for 10 minutes. To the lysed cells, 50 µL of substrate solution i.e., 5 mM of p-nitrophenyl phosphate (pNPP) in 1M diethanolamine and 0.24 mM magnesium chloride (MgCl₂) solution (pH 10.4) was added to all the wells followed by incubation for 1 hour at 37°C. The absorbance of the above solution was read at 405 nm using Synergy HT microplate reader (Biotek, USA). The absorbance values obtained were normalized with substrate blank (pNPP solution alone) absorbance values. The percentage increase in ALP enzyme activity with respect to the untreated cells (baseline group) was calculated using Equation 3:

% Increase in ALP = {(X-R)/R}*100----------------------- (3)

Where,X = Absorbance of cells corresponding to positive control and test groups

R = Absorbance of cells corresponding to baseline group (untreated cells)

HCF cells were used for the estimation of LDH activity. The cells were counted and plated at the density of 0.25 X 106 cells/ well in 24-well plates in cardiac fibroblast specific mediumfollowed by overnight incubation. The cells were then treated with the test formulation combinations/positive control at the non-cytotoxic concentrations for 24 hours. After 24 hours, oxidative stress was given to the cells using 10 mM t-BHP for 3.5 hours. The untreated cells were served as control group, which did not receive any treatment and were maintained in cell growth medium only. Cells treated with 10 mM of t-BHP alone served as the negative control. After 3.5 hours of incubation with t-BHP, the above plates were taken out and LDH activity was determined using LDH activity kit as per manufacturer s instructions. The percent increase in LDH activity was calculated using Equation 4.

% Increase = [(LDH activity_sample-LDH activity_t-BHP)]*100/ [LDH activity_untreated-LDH activity_{t_BHP}].............. (4)

The human hepatoma cells (HepG2) were used for the estimation of ALT activity. The cells were counted and plated at the density of 5 X 10⁴ cells/well in 48-well plates in DMEM media followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations for 24 hours. After 24 hours, oxidative stress was given to the cells using 400 µM t-BHP for 3.5 hours. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 400 µM of t-BHP alone served as negative control. After 3.5 hours of incubation with t-BHP, the above plates were taken out and ALT activity was determined using ALT activity kit as per manufacturer s instructions. The percent increase in ALT activity was calculated using Equation 5.

% Increase = [(ALT activity_sample-ALT activity_t-BHP)]*100/ [ALT activity_untreated-ALT activity_{t_BHP}]............. (5)

The adenocarcinomic human alveolar basal epithelial cells (A549) were used for the estimation of SOD activity. The A549 cells were counted and plated at the density of 1 X 10⁴ cells/well in 24-well plates in DMEM followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations along with 100 µM t-BHP to induce oxidative stress. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 100 µM of t-BHP alone served as negative control. After 24 hours of incubation with t-BHP the above plates were taken out and SOD activity was determined using SOD activity kit as per manufacturer s instructions. The percent increase in SOD activity was calculated using equation 6:

% Increase in SOD activity = ((X-R)/R)*100.............(6)

Where, X = SOD activity corresponding to test item or positive control

R = SOD activity corresponding to Control group.

The human neuroblastoma (SH-SY5Y) cells were used for the estimation of serotonin level. The cells were counted and plated at the density of 10 X 10⁴ cells/well in 96-well plates followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. The treated cells were incubated for 24 hours. Serotonin release was determined by ELISA as per manufacturer s protocol. The percent increase in serotonin levels was calculated using equation 7.

[(X-R)/R]*100................ (7)

Where, X = Serotonin levels corresponding to test item or positive control,

R = Serotonin levels corresponding to control group.

The effect of test formulation on vitamin D receptor (VDR) activity in bone (MG-63) cells were counted using the hemocytometer at density 2 X 10⁵cells/well in 6-well plates followed by overnight incubation. The cells were then sera starved for 24 hours and treated with the test formulation/positive control at the non-cytotoxic concentrations, while control group did not receive any treatment, which were maintained in cell growth medium only. The treated cells were incubated for 24 hours and VDR expression was determined by qPCR using VDR specific primers. Cells were harvested by scrapping and washed with PBS. Cell pellets obtained were analyzed for VDR gene expression using human VDR specific primers: Forward: 5 -GCTGACCTGGTCAGTTACAGCA-3 , Reverse: 5 -CACGTCACTGACGCGGTACTT-3 .VDR gene expression was normalized using House-keeping (HK) reference. Relative quantification (RQ) of VDR gene in Biofield Energy Treated cells was calculated with respect to the untreated cells using equation 8:

RQ = 2-N................ (8)

Where, N is the relative Threshold Cycle (C_T) value of treated sample with respect to the untreated sample.

All the experimental values were presented as percentage. The statistical analysis was performed using SigmaPlot statistical software (v11.0). For two group comparison, student s t-test was used. For multiple group comparison, one-way analysis of variance (ANOVA) was used followed by post-hoc analysis by Dunnett s test. Statistically significant values were set at the level of p≤0.05.

All the cell lines such as MG-63, Ishikawa, A549, HepG2, HCF, and SH-SY5Y were screened for cell viability using MTT assay for safe concentrations. All the tested test concentrations of the test formulation were found safe on the basis of percentage of cell viability. The test criteria for non-cytotoxic test formulation concentration and the positive controls were found to be less than 30% cytotoxicity or greater than 70% cell viability. All the results were considered and represented as safe and non-cytotoxic concentrations. Overall, the experimental data suggested that the overall percent cell viability in different cell-lines were found safe, which were tested for other activities.

The test formulation was screened of cytoprotective activity against three cell lines viz. HCF, HepG2, and A549 cells, while the data was presented in terms of percentage cell protection against t-BHP induced cell damage (Figure 1). Trimetazidine (TMZ) was used as a positive control group in human cardiac fibroblasts cells (HCF) for cytoprotective effect which showed significant restoration of cell viability by 34%, 60%, and 98.3% at 5, 10, and 25 µg/mL, respectively as compared to the t-BHP induced group. Besides, the restoration of cell viability among the tested groups by the test formulation was reported as 60.6%, 46%, and 45.5% at 10, 25.5, and 63.75 µg/mL, respectively in the UT-Med + BT-TI group; while, 67.5% improved cellular restoration at 63.75 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 56.5% and 117.5% improved cellular restoration at 25.5 and 63.75 µg/mL, respectively in the BT-Med + BT-TI group as compared to the untreated test group (UT-Med + UT-TI group). Similarly, silymarin was used as positive control in HepG2 cells, which resulted in significant cellular restoration by 38.4%, 56.6%, and 72.6% at 5, 10, and 25 µg/mL, respectively as compared to the t-BHP induced group. Besides, the test formulation showed restoration of cell viability by 64%, 6.4%, 7.3%, and 10% at 1, 10, 25.5, and 63.75 µg/mL, respectively in the UT-Med + BT-TI group; while, 127.3%, 41.2%, and 16.6% improved cellular restoration at 1, 10, and 25.5 µg/mL respectively, in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 33.3%, 28.4%, and 30.4% improved cellular restoration was observed at 1, 10, and 25.5 µg/mL, respectively in the BT-Med + BT-TI group as compared to the untreated group. Additionally, quercetin was used as positive control in adenocarcinomic human alveolar basal epithelial cells (A549) resulted, restoration of cell viability by 65.7%, 76.7%, and 86.1% at 5, 10, and 25 µg/mL, respectively compared to the t-BHP induced group. Besides, the test formulation showed 605.3% restoration of cell viability at 1 µg/mL in the UT-Med + BT-TI group; while, 314% and 12.5% improved restoration of cell viability at 1 and 10 µg/mL, respectively in the BT-Med + UT-TI group as compared to the UT-Med + UT-TI group. Similarly, 112.3%, 6.5%, and 4.1% improved cellular restoration was reported at 1, 10, and 25.5 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group. These significant values states significant cytoprotective activity after oxidative stress using tert-butyl hydroperoxide (t-BHP). However, this method has been considered as the gold standard for testing the cytoprotective action by stimulation in cell based assay 4142. This cell based activity would reflects that the test formulation could be one of the best tool to protect the cells against injuries 4344, which could protect against many immune related disorders such as cardiovascular diseases, aging, cancer, diabetes, and many more 454647. Thus, Biofield Energy Treatment (The Trivedi Effect^®) can be significantly used to protect the t-BHP induced oxidative stress against the HCF, HepG2, and A549 cells with respect to the cardiotoxicity, hepatotoxicity, and lung cell toxicity. Therefore, the Biofield Energy Healing Treatment could be used against many pathological etiologies such as cardiovascular, liver, and lung diseases.

The test formulation and the test media was tested for ALP activity against two cell lines, MG-63 and Ishikawa cells after Biofield Energy Treatment. Naringenin (nM) was used as positive control in Ishikawa cells, and the results suggested significant increased ALP level by 9.5%, 23.7%, and 130.2% at 0.1, 1, and 10 nM respectively as shown in Figure 2. However, the experimental test groups showed an increased ALP activity by 175.5%, 72.1%, and 60.4% at 0.1, 10, and 50 µg/mL, respectively in the UT-Med + BT-TI group; while, 547.2%, 65.8%, and 30.3% increased ALP activity at 0.1, 10, and 50 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 220.8%, 21.3%, and 39.4% improved ALP level was found at 0.1, 10, and 50 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group in Ishikawa cells. Similarly, calcitriol was used as positive control for MG-63 cells, and the data showed significant improved level of ALP by 13.2%, 21.4%, and 35.4% at 0.1, 1, and 10 nM, respectively. The ALP percent activity in MG-63 cells was significantly increased by 55.1% and 76.9% at 10 and 50 µg/mL, respectively in the UT-Med + BT-TI group as compared to the UT-Med + UT-TI group. Similarly, ALP percent was significantly increased by 6.8%, 51.4%, and 78.4% at 0.1, 10, and 50 µg/mL, respectively in the BT-Med + UT-TI group as compared to the UT-Med + UT-TI group. However, ALP percent was significantly increased by 12%, 51.4%, and 79% at 0.1, 10, and 50 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group in the MG-63 cells. Thus, ALP level was significant improved after treatment with the Biofield Energy Healing Treatment. ALP is one of the important bone health biomarker responsible for controlling various bone disorders 4849 such as low bone density and osteoporosis, osteogenesis imperfect and Paget's disease, which makes bones brittle. Biofield Energy Treatment would be highly recommended option in bone disorders without any adverse effects in comparison with the synthetic drugs.

LDH activity was estimated in HCF cells, and the results after treatment in various experimental groups are presented in terms of improved HCF cellular protection, which represents decreased LDH activity in various groups. The effect of test formulation in different groups with respect to the percent protection of HCF cells in terms of decreased level of lactate dehydrogenase (LDH) activity is presented in the Figure 3. The positive control, trimetazidine (TMZ) showed 34%, 60%, and 98.3% increased cellular protection of HCF cells (decreased of LDH activity) at 5, 10, and 25 µM concentration as compared to the t-BHP group. The protection of HCF cells (decreased of LDH activity) was significantly increased by 60.6%, 46%, and 45.5% at 10, 25.5, and 63.75 µg/mL, respectively in the UT-Med + BT-TI group; while, 67.5% improved cellular protection (decreased of LDH activity) at 63.75 µg/mL in the BT-Med + UT-TI group as compared to the untreated group. Moreover, 56.5% and 117.5% improved cellular protection (decreased of LDH activity) at 25.5 and 63.75 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group. Thus, the results suggested that significant reduced level of LDH activity after Biofield Energy Healing Treatment. LDH activity using HCF cells was significantly reduction after Biofield Energy Treatment that could be useful against various pathological conditions such as tissue injury, necrosis, hypoxia, hemolysis or malignancies. LDH is an enzyme found in all the living cells and found to be responsible for anaerobic cellular respiration. LDH is extensively expressed in most of the body tissues, such as blood cells, skeletal muscle, and heart muscle and play a vital role in tissue injury, necrosis, hypoxia, hemolysis, or malignancies. Besides, LDH is the best biomarker for heart disease or tissue injuries. LDH activity can be best depicted using HCF cells, as these cells play a central role in the extracellular matrix maintenance of the normal heart along with synthesis of growth factors and cytokines 505152.

ALT activity was estimated with the help of HepG2 cell and the results are presented in terms of increased percentage cellular protection (which representsdecreased ALT activity) in the Figure 4. ALT is one of the important liver health enzymes along with kidney, heart, and muscles. Up and down regulation of this enzyme may results in hepatocellular injury and death 53. The positive control, silymarin was in HepG2 cells for ALT activity and the data suggested increased percentage cellular protection of HepG2 cell (decreased ALT activity) by 66.4%, 85.8%, and 114.4% at 5, 10, and 25 µg/mL, respectively. Similarly, the test formulation groups showed improved cellular protection of HepG2 cells (i.e., decreased of ALT activity) by 115.1%, 22.7%, and 16.2% at 1, 10, and 25.5 µg/mL, respectively in the UT-Med + BT-TI group; while, increased cellular protection of HepG2 cells (decreased of ALT activity) by 12.8%, 16.5% and 42.5% at 1, 10, and 25.5 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. An increased cellular protection of HepG2 cells (decreased of ALT activity) by 60.8% and 22.6% at 10 and 25.5 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group (Figure 4). Overall, the results showed significant activity after treatment with the Biofield Energy Healing Treatment. Hepatic cellular damage has been linked with high level of ALT, which affects the cell viability and damage to the cells 54. Biofield Energy Treatment significantly improved the cellular protection with reduced ALT enzyme, which suggests its application in the liver cancer, liver cirrhosis, hepatomegaly, liver failure, and hepatitis.

SOD is one the best antioxidant defense mechanism of the body, which prevent the cellular damage against various types of stress and free radicals, which results in cell death 55. SOD activity was estimated using A549 cells and improved activity denoted increased cellular protection (Figure 5). The positive control, quercetin showed improved percentage increase in the SOD activity with respect to the t-BHP by 12.5%, 53.6%, and 62.1% at 0.1, 1, and 10 µM, respectively. However, the percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 191.1%, 27.9%, and 47.4% at 0.1, 1, and 10 µg/mL, respectively in the UT-Med + BT-TI group; while, increased SOD activity by 34.5% and 14.3% at 0.1 and 10 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. Moreover an increased SOD activity by 81.4% and 20.1% at 0.1 and 10 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group (Figure 5). The present experimental data revealed that the Biofield Energy Treatment has significantly improved the SOD antioxidant defense activity, which could protect from many respiratory diseases such as pneumonia, asthma, pulmonary fibrosis, and lung cancer.

Serotonin is supposed to be responsible for many neuropsychiatric disorders (viz. Alzheimer's disease, cognitive health, loss of ability of thinking, depression, memory loss, etc.) along with various neuronal disorders like sleep, feeding, pain, sexual behavior, cardiac regulation, and cognition 56. Serotonin assay was performed using SH-SY5Y cells and the effect of test formulation and cell line media was assessed after 24 hours of treatment using ELISA assay. Serotonin activity was tested and the data is presented in the Figure 6. Curcumin was used a positive control, showed 112.8%, 127.2%, and 160.2% increased the level of serotonin at 0.1, 1, and 5 µM, respectively compared to the vehicle control (VC) group. The data showed significant increased serotonin level by 31.8%, 17.6%, and 9.6% at 10, 25.5, and 63.75 µg/mL, respectively in the UT-Med + BT-TI group; while, significantly increased serotonin level by 18.3% and 8% at 10 and 63.75 µg/mL, respectively in the BT-Med + UT-TI group as compared to untreated group. Moreover, 56.9% and 40.2% improved serotonin level at 25.5 and 63.75 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group (Figure 6). Overall, the present experiment showed that the serotonin level was significantly improved in the entire tested group. Our research study showed significant improved level of serotonin after treatment with the Biofield Energy Healing Treated test formulation that would be highly useful against various neurodegenerative diseases.

Human bone osteosarcoma cells (MG-63) was used for evaluation of the VDR activity against the Biofield Energy Treated test formulation. The expression of VDRs was studies using the phenomenon of ligand binding through vitamin D active molecule, which was estimated using quantitative-polymerase chain reaction (qPCR) amplification. Using real time PCR, different VDR-relative threshold cycle (VDR-C_T) values were obtained after complete amplification cycles using specific primer probes. Relative quantification (RQ) was calculated from the VDR-C_T and house-keeping (HK)-C_T values in MG-63 cells. The values after treated with the Biofield Energy Treated and untreated test formulation and positive control are represented in the Figure 7. Calcitriol was used as a positive control and the RQ of VDR was found to be increased in concentration-dependent manner by 22.3%, 46.4%, and 171.3% at 1, 10, and 100 nM, respectively. The experimental test groups showed increased RQ of VDR expression by 304.3%, 277.7%, and 229.4% in the UT-Med + BT-TI group at 0.01, 0.1, and 1 µg/mL, respectively; while, 40.3%, 128.4%, and 86.4% increased RQ of VDR at 0.01, 0.1, and 1 µg/mL, respectively in the BT-Med + UT-TI group as compared to the untreated group. Moreover, an increased RQ of VDR by 240% and 221.8% at 0.1 and 1 µg/mL, respectively in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group. Overall, it can be concluded from this activity, that VDR expression was significantly improved in MG-63 after treatment with the test formulation. Calcitriol was reported to bind with the VDRs and extensively regulates the calcium homeostasis, immunity, overall cellular growth, and differentiation 57. Calcitriol controls various calcium metabolisms and play a vital role in improving quality of life and overall bone cell growth and development 5859. The Trivedi Effect^® would be the best alternative treatment approach for bone related disorders.